Immunogenicity of biological agents in inflammatory bowel disease.
Fefferman
David S
DS
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. dfefferm@bidmc.harvard.edu
Farrell
Richard J
RJ
D000906:Antibodies / Q000097:blood; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D001688:Biological Products / Q000627:therapeutic use; D003424:Crohn Disease / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D000069285:Infliximab; D007263:Infusions, Parenteral
D000906:Antibodies; D000911:Antibodies, Monoclonal; D001688:Biological Products; D005765:Gastrointestinal Agents; D000069285:Infliximab